HCW Biologics Inc
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat p… Read more
HCW Biologics Inc (HCWB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 1.538x
Based on the latest financial reports, HCW Biologics Inc (HCWB) has a cash flow conversion efficiency ratio of 1.538x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.24 Million) by net assets ($-2.11 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
HCW Biologics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how HCW Biologics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
HCW Biologics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HCW Biologics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DCM Financial Services Limited
NSE:DCMFINSERV
|
0.000x |
|
Zenicor Medical Systems AB
ST:ZENI
|
-0.087x |
|
Diamcor Mining Inc
OTCQB:DMIFF
|
-0.005x |
|
AIRA Factoring Public Company Limited
BK:AF
|
-0.265x |
|
NEXANS - Dusseldorf Stock Exchang
DU:NXS
|
N/A |
|
Enersize Oy
ST:ENERS
|
-12.911x |
|
Capital Appreciation Ltd
JSE:CTA
|
0.111x |
|
MACQUARIE GRP
BE:4M4
|
N/A |
Annual Cash Flow Conversion Efficiency for HCW Biologics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of HCW Biologics Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-6.77 Million | $-14.23 Million | 2.101x | +225.65% |
| 2023-12-31 | $13.46 Million | $-22.51 Million | -1.672x | -502.70% |
| 2022-12-31 | $37.43 Million | $-10.39 Million | -0.277x | -29.43% |
| 2021-12-31 | $51.19 Million | $-10.98 Million | -0.214x | +70.41% |
| 2020-12-31 | $14.40 Million | $-10.43 Million | -0.725x | +3.61% |
| 2019-12-31 | $9.00 Million | $-6.77 Million | -0.752x | -- |